Cellectis (CLLS) Accumulated Depreciation & Amortization (2014 - 2025)
Cellectis (CLLS) posted Accumulated Depreciation & Amortization of -$11.3 million for Q4 2025, down 5.44% on a QoQ basis from -$10.7 million in Q4 2024, and down 5.44% year-over-year from -$12.0 million in Q4 2024.
Cellectis (CLLS) has 12 years of Accumulated Depreciation & Amortization data on file, last reported at -$11.3 million in Q4 2025.
- In Q4 2025, Accumulated Depreciation & Amortization fell 5.44% year-over-year to -$11.3 million; the TTM figure through Dec 2025 stood at -$11.3 million (down 5.44% YoY), while the FY2025 annual figure was -$11.3 million, down 5.44% from the prior year.
- Accumulated Depreciation & Amortization declined to -$11.3 million in Q4 2025, from -$10.7 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $11.2 million in Q4 2022 and bottomed at -$11.3 million in Q4 2025.
- A 5-year average of -$2.7 million and a median of -$10.1 million in 2023 frame the typical range for Accumulated Depreciation & Amortization.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation & Amortization jumped 53.55% — and 2023, when it slumped 190.09%.
- Year by year, Accumulated Depreciation & Amortization stood at $7.3 million in 2021, then jumped by 53.55% to $11.2 million in 2022, then tumbled by 190.09% to -$10.1 million in 2023, then retreated by 6.74% to -$10.7 million in 2024, then dropped by 5.44% to -$11.3 million in 2025.
- The last three Accumulated Depreciation & Amortization figures came in at -$11.3 million (Q4 2025), -$10.7 million (Q4 2024), and -$10.1 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.33 Mn |
| Dec 31, 2025 | -11.33 Mn |
| Dec 31, 2024 | -10.74 Mn |
| Dec 31, 2024 | -10.74 Mn |
| Dec 31, 2023 | -10.06 Mn |
| Dec 31, 2023 | -10.06 Mn |
| Dec 31, 2022 | 11.17 Mn |
| Dec 31, 2022 | 11.17 Mn |
| Dec 31, 2021 | 7.28 Mn |
| Dec 31, 2021 | 7.28 Mn |
| Dec 31, 2020 | 21.37 Mn |
| Dec 31, 2020 | 21.37 Mn |
| Dec 31, 2019 | 17.82 Mn |
| Dec 31, 2019 | 17.82 Mn |
| Dec 31, 2018 | 17.43 Mn |
| Dec 31, 2018 | 17.43 Mn |
| Dec 31, 2017 | 14.88 Mn |
| Dec 31, 2017 | 14.88 Mn |
| Dec 31, 2016 | 411,218.45 |
| Dec 31, 2016 | 411,218.45 |
| Dec 31, 2015 | 37,719.43 |
| Dec 31, 2015 | 37,719.43 |
| Dec 31, 2014 | 93,065.39 |
| Dec 31, 2014 | 93,065.39 |